Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 6/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27018056 | 0.90 | MRGPRX4 (0.40) | HSPB1TRPA1 | |
| SCHEMBL23249850 | 0.78 | HSPB1 (0.44) | HSPB1TRPA1 | |
| SCHEMBL23263220 | 0.73 | GAA (0.44) | BRD4 | |
| SCHEMBL10456772 | 0.73 | TRPA1 (0.56) | HSPB1TRPA1 | |
| SCHEMBL27018675 | 0.73 | PIK3CD (0.42) | — | |
| SCHEMBL11123942 | 0.73 | ALDH1A1 (0.46) | TRPA1 | |
| SCHEMBL23263198 | 0.72 | HSPB1 (0.41) | HSPB1TRPA1MAPTBRD4 | |
| SCHEMBL9369451 | 0.70 | KMT2A (0.47) | HSPB1TRPA1MAPT | |
| SCHEMBL27018576 | 0.70 | BRD4 (0.45) | MAPTBRD4 | |
| SCHEMBL921819 | 0.69 | ALDH1A1 (0.62) | TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073131-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4045025-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TXNRD1, SDHB | HSPB1 485/4885TRPA1 3835/4885MAPT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.